Baynes Roy D.
SEC Form 4 insider trading activity
Baynes Roy D. has filed 11 SEC Form 4 filings (32 transaction rows) across 2 companies, including NTRA, TVTX, with disclosures dating back to 2025. 11 of those filings fall inside the rolling window. Most recent filing: Jul 1, 2026.
On the most recent filing, Baynes Roy D. is listed as Director at Travere Therapeutics, Inc. Inside the rolling window, Baynes Roy D. reported no open-market purchases and 7 open-market sales totaling $5.4M in TVTX and NTRA. The largest disclosed transaction in the window is a sale of 7,668 NTRA shares on Nov 20, 2025, worth $1.7M.
Companies traded
Other insiders at NTRA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$5.4M
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Baynes Roy D. made?
Baynes Roy D. has filed 11 SEC Form 4 filings (32 transaction rows) across 2 companies, including NTRA, TVTX since 2025.
Which companies does Baynes Roy D. trade?
Baynes Roy D. has filed SEC Form 4 disclosures for 2 companies, including NTRA, TVTX.
When was Baynes Roy D.'s most recent SEC Form 4 filing?
Baynes Roy D.'s most recent SEC Form 4 filing on Tracefour is dated Jul 1, 2026.
What is Baynes Roy D.'s total buy and sell value in the current window?
Inside the rolling retention window, Baynes Roy D. bought $0 and sold $5.4M based on SEC Form 4 filings.
What was Baynes Roy D.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 7,668 NTRA shares on 2025-11-20, worth $1.7M, per SEC Form 4 filings.